https://www.selleckchem.com/pr....oducts/b102-parp-hda
In the multivariate analysis, mesothelin expression and co-expression were poor prognostic factors for PFS (mesothelin expression hazard ratio [HR] = 2.14, p 0.01; co-expression HR = 2.19, p 0.01) and OS (mesothelin expression HR = 2.18, p 0.01; co-expression HR = 2.22, p 0.01). Mesothelin expression and co-expression might be associated with tumor aggressiveness and poor prognosis in patients with endometrial carcinoma. Persons with mesothelin-expressing endometrial cancers present a particularly high me
Curtir
Comentario
Compartilhar
